|Protocol #||Sponsor||Protocol Title|
EMR 100070-001, 2013-002834-19
|A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE Series)
|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations (SIGNATURE Series)
The trials listed in this section are not limited to one “primary” organ site of cancer origin. Trials listed here are testing new cancer treatments from multiple different primary organ sites. Some trials, such as Novartis Signature Series, are selected by specific pathway “driver” mutations based upon molecular analysis of the patient’s tumor. These trials are testing a “personalized” or “precision” approach to treating a patient’s specific cancer based upon its molecular fingerprint.